Heron Therapeutics, Inc. (HRTX) by event type
HRTX moves most on analyst downgrades — a median of -2.79% at 30 minutes across 18 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the HRTX overview →
How HRTX reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 1,101 of 2,717 | 12 | +0.09% | 58% | -0.61% |
| Analyst downgrades 2,560 of 2,603 | 18 | -2.79% | 22% | -4.10% |
| Rating reiterations 3,144 of 3,522 | 26 | -0.31% | 46% | +0.66% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how HRTX usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Rating reiterations → · HRTX overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kala Pharmaceuticals, Inc. (KALA) | 248 | +0.41% | 56% |
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.